The type of DNA damage response after decitabine treatment depends on the level of DNMT activity
Life Science Alliance · 2024-09 · 7 (9) · e202302437
DOI: 10.26508/lsa.202302437 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, online erschienen am 21.06.2024. Verfasst von Tina Aumer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chemical Epigenetics Munich, Department of Chemistry, University of Munich (LMU), München, Germany. Hauptthemen laut MEDLINE: Decitabine, DNA Damage, DNA Repair, DNA Methylation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Daimler und Benz Stiftung, Fonds der Chemischen Industrie.
Abstract (Originalsprache)
Decitabine and azacytidine are considered as epigenetic drugs that induce DNA methyltransferase (DNMT)-DNA crosslinks, resulting in DNA hypomethylation and damage. Although they are already applied against myeloid cancers, important aspects of their mode of action remain unknown, highly limiting their clinical potential. Using a combinatorial approach, we reveal that the efficacy profile of both compounds primarily depends on the level of induced DNA damage. Under low DNMT activity, only decitabine has a substantial impact. Conversely, when DNMT activity is high, toxicity and cellular response to both compounds are dramatically increased, but do not primarily depend on DNA hypomethylation or RNA-associated processes. By investigating proteome dynamics on chromatin, we show that decitabine induces a strictly DNMT-dependent multifaceted DNA damage response based on chromatin recruitment, but not expression-level changes of repair-associated proteins. The choice of DNA repair pathway hereby depends on the severity of decitabine-induced DNA lesions. Although under moderate DNMT activity, mismatch (MMR), base excision (BER), and Fanconi anaemia–dependent DNA repair combined with homologous recombination are activated in response to decitabine, high DNMT activity and therefore immense replication stress induce activation of MMR and BER followed by non-homologous end joining.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Chemical Epigenetics Munich, Department of Chemistry, University of Munich (LMU), München, Germany.
- TUM School of Natural Sciences, Technical University of Munich (TUM), München, Germany.
- Department of Biochemistry, University of Munich (LMU), München, Germany.
- Department of Ophthalmology, University Hospital LMU Munich, München, Germany.
- Institute of Chemical Epigenetics Munich, Department of Chemistry, University of Munich (LMU), München, Germany franziska.traube@ibtb.uni-stuttgart.de.
- Institute of Biochemistry and Technical Biochemistry, University of Stuttgart, Stuttgart, Germany.
ORCID-Profile: Maike Däther, Linda Bergmayr, Stephanie Kartika, Theodor Zeng, Qingyi Ge, Alexander J Hess, Stylianos Michalakis, Franziska R Traube
Förderung
- Deutsche Forschungsgemeinschaft
- Daimler und Benz Stiftung
- Fonds der Chemischen Industrie
- TUM Junior Fellows Fond
Zitieren
APA
Aumer, T., Däther, M., Bergmayr, L., Kartika, S., Zeng, T., Ge, Q., Giorgio, G., Hess, A. J., Michalakis, S., & Traube, F. R. (2024). The type of DNA damage response after decitabine treatment depends on the level of DNMT activity. Life Science Alliance, 7(9), e202302437. https://doi.org/10.26508/lsa.202302437
Vancouver
Aumer T, Däther M, Bergmayr L, Kartika S, Zeng T, Ge Q, et al. The type of DNA damage response after decitabine treatment depends on the level of DNMT activity. Life Science Alliance. 2024;7(9):e202302437. doi:10.26508/lsa.202302437
BibTeX
@article{Aumer2024,
author = {Aumer, Tina and Däther, Maike and Bergmayr, Linda and Kartika, Stephanie and Zeng, Theodor and Ge, Qingyi and Giorgio, Grazia and Hess, Alexander J and Michalakis, Stylianos and Traube, Franziska R},
title = {The type of DNA damage response after decitabine treatment depends on the level of DNMT activity},
journal = {Life Science Alliance},
year = {2024},
volume = {7},
number = {9},
pages = {e202302437},
doi = {10.26508/lsa.202302437}
}
EUVIMED